Coated medical device

• US 7,967,855 B2
• Filed: 11/18/2005
• Issued: 06/28/2011
• Est. Priority Date: 07/27/1998
• Status: Expired due to Fees

• Current Assignee: Mirus LLC
• Original Assignee: ICON Interventional Systems, Inc.
• Inventors: Brodbeck, William G., Furst, Joseph G.
• Primary Examiner(s): Bui; Vy Q
• Application Number:
  US11/283,330
• Publication Number:
  US 20060136051A1
• Time in Patent Office: 2,048 Days
• Field of Search: 623/1.15, 623/1.42, 623/1.46, 606/191, 606/194, 606/195, 606/198
• US Class Current: 623/1.42
• CPC Class Codes: A61F 2/91 made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
• CPC Class Codes: A61F 2/915 with bands having a meander structure, adjacent bands being connected to each other
• CPC Class Codes: A61F 2002/91516 the meander having a change in frequency along the band
• CPC Class Codes: A61F 2002/91525 within the whole structure different bands showing different meander characteristics, e.g. frequency or amplitude
• CPC Class Codes: A61F 2002/91533 characterised by the phase between adjacent bands
• CPC Class Codes: A61F 2002/91575 connected peak to trough
• CPC Class Codes: A61F 2220/0008 Fixation appliances for connecting prostheses to the body
• CPC Class Codes: A61F 2230/0054 V-shaped
• CPC Class Codes: A61F 2250/0068 the pharmaceutical product being in a reservoir

Abstract

A stent that is adapted for introduction into a body passageway and which releases at least one biological agent after being inserted in the body passageway. The release of the at least one biological agent can be a controlled release via molecular diffusion through a non-porous polymer layer.

Claims

1. A stent adapted for introduction into a body passageway of a patient, said stent comprising a base structure, biological agent and polymer;

said base structure including at least one of said biological agent coated on at least a portion of said base structure, at least one layer of polymer coated on at least a portion of said base structure or combinations thereof;

said at least one biological agent at least partially mixed with said polymer, over-coated with a layer of said polymer or combinations thereof;

said polymer including a non-porous polymer, said non- porous polymer having a molecular weight, molecular structure, layer thickness or combinations thereof to at least partially control a rate of release of said biological agent from said stent by a molecular diffusion process, said base structure including a surface structure, a micro-structure, an internal structure, or combinations thereof that are formed on or secured to said base structure, a plurality of said micro-structures extend upwardly from and above an outer surface of said base structure, said plurality of microstructures having a shape and size designed to penetrate into said body passageway at a treatment site when said base structure is expanded to an expanded cross-sectional area and to deliver said biological agent in said penetrated region of said body passageway, said plurality of microstructures having a height of less than 400 microns, said micro-structures at least partially coated with biological agent, at least partially made of biological agent, includes biological agent in an internal passage of said micro-structure, or combinations thereof;

wherein said biological agent is present on said stent in an amount of about 20 microgram-100 microgram per mm²; and

wherein a polymer layer that at least partially control a release of at least one of said biological agents from said stent, said polymer layer having a thickness of about 0.1-30 microns.

2. The stent as defined in claim 1, wherein said non-porous polymer includes parylene, parylene C, parylene N, parylene F, parylene derivatives, parylene C derivatives, parylene N derivatives, parylene F derivatives, or combinations thereof.

3. The stent as defined in claim 2, wherein said biological agent includes trapidil, trapidil derivatives, GM-CSF, GM-CSF derivatives, or combinations thereof.

4. The stent as defined in claim 3, wherein said biological agent includes trapidil, trapidil derivatives, or combinations thereof.

5. The stent as defined in claim 4, wherein said biological agent additionally includes GM-CSF, GM-CSF derivatives.

6. The stent as defined in claim 5, wherein said polymer includes at least two polymers selected from the group consisting of parylene, parylene C, parylene N, parylene F, parylene derivatives, parylene C derivatives, parylene N derivatives, parylene F derivatives, or combinations thereof.

7. The stent as defined in claim 4, wherein said polymer includes at least two polymers selected from the group consisting of parylene, parylene C, parylene N, parylene F, parylene derivatives, parylene C derivatives, parylene N derivatives, parylene F derivatives, or combinations thereof.

8. The stent as defined in claim 1, wherein said biological agent includes trapidil, trapidil derivatives, GM-CSF, GM-CSF derivatives, or combinations thereof.

9. The stent as defined in claim 1, wherein the outer surface of polymer layer includes at least one layer of biological agent.

10. The stent as defined in claim 9, wherein said base structures includes at least one internal structure, said at least one internal structure including biological agent.

11. The stent as defined in claim 1, wherein said base structure is at least partially plasma etched, electro-polished, or combinations thereof.

12. A stent adapted for introduction into a body passageway of a patient, said stent comprising a base structure, a first biological agent and a first polymer;

said base structure including a) said first biological agent coated on at least a portion of said base structure, b) said first polymer coated on at least a portion of said base structure, and combinations;

said first biological agent at least partially a) mixed with said first polymer, b) over-coated with a layer of said first polymer, and combinations thereof;

at least a portion of said base structure including said first biological agent coated on at least a portion of said base structure and said layer of said first polymer is at least partially over-coated on said first biological agent;

said first polymer including a non- porous polymer, said non-porous first polymer having a) a molecular weight, b) molecular structure, c) layer thickness, and combinations thereof to at least partially control a rate of release of said first biological agent from said stent by a molecular diffusion process, said base structure including a plurality of micro-structures that are formed on or secured to said base structure and which extend upwardly from and above an outer surface of said base structure, said plurality of microstructures having a shape and size designed to penetrate into said body passageway at a treatment site when said base structure is expanded to an expanded cross-sectional area and to deliver said biological agent in said penetrated region of said body passageway, said plurality of microstructures having a height of less than 300 microns, a plurality of said micro-structures include biological agent in an internal passage of said micro-structure;

wherein said biological agent is present on said stent in an amount of about 20 microgram-100 microgram per mm²; and

wherein said layer of said first polymer has a thickness of about 0.1-30 microns.

13. The stent as defined in claim 12, wherein said first polymer includes one or more polymers selected from the group consisting of parylene, parylene C, parylene N, parylene F, parylene derivatives, parylene C derivatives, parylene N derivatives, and parylene F derivatives.

14. The stent as defined in claim 13, wherein said first biological agent includes one or more agents selected from the group consisting of trapidil, trapidil derivatives, GM-CSF, and GM-CSF derivatives.

15. The stent as defined in claim 14, wherein said first biological agent includes one or more agents selected from the group consisting of trapidil and trapidil derivatives.

16. The stent as defined in claim 15, wherein said first biological agent additionally includes one or more agents selected from the group consisting of GM-CSF and GM-CSF.

17. The stent as defined in claim 16, wherein an outer surface of said first polymer layer includes a layer of a second biological agent.

18. The stent as defined in claim 16, wherein said base structure includes a third biological agent.

19. The stent as defined in claim 18, wherein said base structures includes said micro-structure, said micro-structure at least partially a) coated with said third biological agent, b) at least partially made of said third biological agent, c) includes said third biological agent in an internal passage of said micro-structure, and combinations thereof.

20. The stent as defined in claim 15, wherein an outer surface of said first polymer layer includes a layer of a second biological agent.

21. The stent as defined in claim 20, wherein said base structure includes a third biological agent.

22. The stent as defined in claim 21, wherein said base structures includes said micro-structure, said micro-structure at least partially a) coated with said third biological agent, b) at least partially made of said third biological agent, c) includes said third biological agent in an internal passage of said micro-structure, and combinations thereof.

23. The stent as defined in claim 12, wherein said base structure includes a third biological agent.

24. The stent as defined in claim 23, wherein said base structures includes said micro-structure, said micro-structure at least partially a) coated with said third biological agent, b) at least partially made of said third biological agent, c) includes said third biological agent in an internal passage of said micro-structure, and combinations thereof.

25. The stent as defined in claim 12, wherein an outer surface of said first polymer layer includes a layer of a second biological agent.

26. The stent as defined in claim 12, wherein said base structure includes a third biological agent.

27. The stent as defined in claim 26, wherein said base structures includes said micro-structure, said micro-structure at least partially a) coated with said third biological agent, b) at least partially made of said third biological agent, c) includes said third biological agent in an internal passage of said micro-structure, and combinations thereof.

28. The stent as defined in claim 27, wherein said first biological agent, said second biological agent, and said third biological agent are the same.

29. The stent as defined in claim 27, wherein said first biological agent, said second biological agent, and said third biological agent are different.

30. The stent as defined in claim 27, wherein said first biological agent and said second biological agent are different.

31. The stent as defined in claim 27, wherein said second biological agent and said third biological agent are different.

32. The stent as defined in claim 27, wherein said first biological agent and said third biological agent are different.

33. The stent as defined in claim 12, wherein said base structure is at least partially plasma etched, electro-polished, and combinations thereof.